1. Home
  2. SCLX vs CIK Comparison

SCLX vs CIK Comparison

Compare SCLX & CIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$19.15

Market Cap

139.3M

Sector

Health Care

ML Signal

HOLD

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

HOLD

Current Price

$2.82

Market Cap

154.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
CIK
Founded
2011
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
139.3M
154.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SCLX
CIK
Price
$19.15
$2.82
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
122.8K
115.4K
Earning Date
11-14-2025
01-01-0001
Dividend Yield
N/A
9.03%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,360,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$749.70
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.60
$2.50
52 Week High
$34.27
$3.19

Technical Indicators

Market Signals
Indicator
SCLX
CIK
Relative Strength Index (RSI) 51.13 47.59
Support Level $18.34 $2.81
Resistance Level $20.62 $2.85
Average True Range (ATR) 2.22 0.03
MACD -0.02 0.01
Stochastic Oscillator 32.91 72.64

Price Performance

Historical Comparison
SCLX
CIK

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

Share on Social Networks: